LTFS
DNLI icon

Ladenburg Thalmann Financial Services’s Denali Therapeutics DNLI Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$3K Hold
200
– – ﹤0.01% 4947
2019
Q3 		$3K Hold
200
– – ﹤0.01% 4843
2019
Q2 		$4K Hold
200
– – ﹤0.01% 4766
2019
Q1 		$5K Hold
200
– – ﹤0.01% 4644
2018
Q4 		$4K Hold
200
– – ﹤0.01% 4669
2018
Q3 		$4K Buy
+200
New +$3.31K ﹤0.01% 4664

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Ladenburg Thalmann Financial Services's DNLI Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Denali Therapeutics (DNLI) position steady in Q4 2019 at 200 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #4947.

Ladenburg Thalmann Financial Services first reported a position in DNLI in Q3 2018 and has held it in 6 quarters since. The position peaked at $5K in Q1 2019. 108 funds tracked by Wall St. Rank hold DNLI as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 200 shares of Denali Therapeutics worth $3K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its Denali Therapeutics share count unchanged in Q4 2019.
  • Denali Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4947 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Denali Therapeutics in Q3 2018 and has held it in 6 quarters since.
  • Ladenburg Thalmann Financial Services's Denali Therapeutics position peaked at $5K in Q1 2019.
  • 108 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.